ReShape Lifesciences Inc. financial data

Symbol
RSLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
1001 Calle Amanecer, San Clemente, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
OBALON THERAPEUTICS INC (to 6/21/2021)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 204 % +13.4%
Quick Ratio 92.2 % +62.7%
Debt-to-equity 96.6 % -20.9%
Return On Assets -91.5 % +58.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 713K shares -94.6%
Common Stock, Shares, Outstanding 705K shares -79.6%
Entity Public Float 5.07M USD -52.4%
Common Stock, Value, Issued 29K USD +867%
Weighted Average Number of Shares Outstanding, Basic 509K shares +755%
Weighted Average Number of Shares Outstanding, Diluted 509K shares +755%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.18M USD -16.6%
Research and Development Expense 2.02M USD -0.83%
General and Administrative Expense 7.67M USD -40.7%
Operating Income (Loss) -7.92M USD +73.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7M USD +73.3%
Income Tax Expense (Benefit) 66K USD +100%
Net Income (Loss) Attributable to Parent -7.07M USD +73%
Earnings Per Share, Basic 56.8 USD/shares +94.8%
Earnings Per Share, Diluted 56.8 USD/shares +94.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 743K USD -48.7%
Accounts Receivable, after Allowance for Credit Loss, Current 1.3M USD
Inventory, Net 2.93M USD -8.43%
Other Assets, Current 51K USD -45.7%
Assets, Current 5.34M USD -27.9%
Deferred Income Tax Assets, Net 28K USD -49.1%
Property, Plant and Equipment, Net 43K USD -38.6%
Operating Lease, Right-of-Use Asset 177K USD -35.4%
Other Assets, Noncurrent 29K USD 0%
Assets 5.62M USD -28.3%
Accounts Payable, Current 2.11M USD +44%
Employee-related Liabilities, Current 702K USD -30.8%
Accrued Liabilities, Current 1.64M USD -39.9%
Liabilities, Current 4.03M USD -9.94%
Deferred Income Tax Liabilities, Net 367K USD -40.3%
Operating Lease, Liability, Noncurrent 77K USD -56%
Liabilities 4.13M USD -13%
Accumulated Other Comprehensive Income (Loss), Net of Tax -88K USD +6.38%
Retained Earnings (Accumulated Deficit) -641M USD -1.12%
Stockholders' Equity Attributable to Parent 1.49M USD -51.8%
Liabilities and Equity 5.62M USD -28.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.07M USD +59.1%
Net Cash Provided by (Used in) Financing Activities 10.2M USD
Net Cash Provided by (Used in) Investing Activities -7K USD -100%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 705K shares -79.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.08M USD -141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 843K USD -45.6%
Deferred Tax Assets, Valuation Allowance 76.9M USD +5.42%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 77M USD +5.28%
Operating Lease, Liability 191K USD -33%
Depreciation 6K USD -83.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.06M USD +73%
Lessee, Operating Lease, Liability, to be Paid 202K USD -35.3%
Property, Plant and Equipment, Gross 150K USD -85.4%
Operating Lease, Liability, Current 114K USD +3.64%
Lessee, Operating Lease, Liability, to be Paid, Year Two 59K USD -48.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 115K USD +3.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 1K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11K USD -59.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD
Deferred Tax Assets, Operating Loss Carryforwards 67.9M USD +7.11%
Preferred Stock, Shares Authorized 10M shares +100%
Unrecognized Tax Benefits 1.05M USD 0%
Operating Lease, Payments 27K USD -69%
Additional Paid in Capital 643M USD +0.86%
Amortization of Intangible Assets 33K USD -98.2%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -48.6%
Share-based Payment Arrangement, Expense 281K USD -68.6%